Ipsen

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search

Ipsen
Public
Traded as EuronextIPN
CAC Mid 60 Component
Industry Pharmaceutical
Founded 1929
Headquarters Paris, France
Key people
Marc de Garidel (Non-executive Chairman) David Meek (Chief Executive Officer)
Products  
Number of employees
5,400
Website www.ipsen.com

Ipsen is a French pharmaceutical company headquartered in Paris, France.[1]

It develops and markets medications used in oncology, neuroscience and rare diseases along with consumer healthcare products.[1]

It is publicly traded on the Euronext Paris as part of the SBF 120 index.[1]

Ipsen has about 5,400 employees worldwide.

Overview

Ipsen is a global specialty-driven pharmaceutical company with total sales exceeding €1.9 billion in 2017.[citation needed]

Ipsen's ambition is to become a leader in specialty healthcare solutions for targeted debilitating diseases.[citation needed] Its development strategy is supported by 3 franchises: oncology, neuroscience and rare diseases. Ipsen's R&D is focused on its innovative and differentiated technological platforms located in major biotechnological and life science hubs (Paris-Saclay in France, Oxford in the UK, Cambridge in the USA).

The Beaufour family, which ranks as the 42nd richest family in France, still owns 57% of its shares and 73% of its voting rights,[2] and two of its members, Anne Beaufour and Henri Beaufour, sit on its board of directors.[3][4][5]

The Board of Directors of Ipsen has appointed David Meek as Chief Executive Officer, effective July 18, 2016.[6] Former CEO Marc de Garidel assumes the role of non-executive chairman and continues to serve the Board of Directors through his deep industry expertise. In addition, Marc de Garidel will advise Mayroy, the Ipsen controlling holding company.[7][8]

In 2017, Ipsen spent close to €266 million—13.9% of consolidated sales—on research and development.

In February 2015, the company announced it would Canbex Therapeutics $6.8 million upfront upon completion of a Phase IIA study of Canbex’s lead multiple sclerosis compound, VSN16R.[9]

in October 2016, European Commission approves Ipsen’s Cabometyx (Cabozantinib) Tablets for the treatment of advanced renal cell carcinoma (RCC) in adults following prior vascular endothelial growth factor (VEGF)-targeted therapy.[10]

The CABOSUN study, presented at the European Society for Medical Oncology (ESMO) 2016 congress, showed Cabometyx (Cabozantinib) can decrease the rate of disease progression or death by 31% in advanced renal cell carcinoma (RCC).[11]

In November 2018, the European Commission (EC) approved Cabometyx (cabozantinib) 20, 40, 60 mg as a monotherapy for hepatocellular carcinoma (HCC) in adults who have previously been treated with sorafenib. This approval allows for the marketing of Cabometyx (cabozantinib) in this indication in all 28 member states of the European Union, Norway and Iceland.

End 2017, Ipsen's global presence spans 115 countries. US is the number one affiliate with €454m sales.[12]

Research and development

In 2017, Ipsen’s R&D expenditure totaled close to €266 million, representing more than 13.9% of Group sales.

Ipsen's main research and development centers are located in Cambridge (Massachusetts, United States), Milton Park / Oxford (United Kingdom) and Paris Saclay (France).

Key figures

  • 2017 revenue: €1.9 billion
  • Products: 20 drugs marketed
  • R&D: 266 million euros invested in R&D in 2017 (13,9% of revenue)
  • Number of employees: 5400 employees

Breakdown by activity:

  • Specialty care: €1.591 million, (83% of revenue)
  • Consumer Healthcare: €316.8 million , (17% of revenue)

Governance

Board of directors

The Board of Directors sets the strategic guidelines for Ipsen’s activities and oversees implementation.

Management team

Corporate executives are responsible for managing the Group’s operations and coordinating the Group’s various scientific, legal, financial, commercial and strategic actions.

  • David Meek, CEO since July 2016.
  • François Garnier, Executive Vice President, General Counsel
  • Benoît Hennion, Executive Vice President, Consumer Healthcare
  • Dominique Laymand, Executive Vice President, Chief Ethics and Compliance Officer
  • Dr Alexandre Lebeaut, Executive Vice President, Research and Development, Chief Scientific Officer
  • Aymeric Le Chatelier, Executive Vice President, Chief Financial Officer
  • Ivana Magovcevic-Liebisch, Executive Vice President, Chief Business Officer
  • Christopher Masterson, Senior Vice-President, Quality
  • Régis Mulot, Executive Vice President, Chief Human Resources Officer
  • Aidan Murphy, Executive Vice President, Technical Operations
  • Richard Paulson, Executive Vice President, Chief Executive Officer in Ipsen North America
  • Harout Semerjian, Executive Vice President, Chief Commercial Officer
  • Didier Véron, Senior Vice President, Public Affairs and Corporate Communication
  • Heather White, Vice President, Global Internal Audit

Ipsen Foundation

In 1983, Ipsen founded the Ipsen Foundation (Fondation Ipsen) with the help of the Fondation de France to track progress in biomedical research.[13][14] It is headquartered in Boulogne-Billancourt.[13][14] It has organised 64 colloquia, and it has partnered with the World Health Organization, the Fondation Nationale de Gérontologie, Harvard University, the Salk Institute for Biological Studies, the Massachusetts General Hospital, and the academic journals Nature and Cell.[13]

References

  1. ^ a b c Official website, Key Figures Archived 1 February 2013 at the Wayback Machine.. Ipsen.com.
  2. ^ [1]
  3. ^ Challenges wealth ranking. Challenges.fr.
  4. ^ Challenges. Challenges.fr.
  5. ^ a b c d e f g h i j k l Board of Directors Archived 1 February 2013 at the Wayback Machine.. Ipsen.com.
  6. ^ [2] Marc de Garidel, non-executive chairman
  7. ^ [3] David Meek appointed CEO Ipsen
  8. ^ [4] Marc de Garidel q2 2016 result earnings call transcript
  9. ^ http://www.genengnews.com/gen-news-highlights/ipsen-gains-option-to-buy-canbex-therapeutics-for-6-8m/81250959/
  10. ^ [5] European Commission approves Ipsen’s Cabometyx for treatment of advanced renal cell carcinoma
  11. ^ [6] Ipsen eyes first-line licence for new advanced kidney cancer drug Cabometyx
  12. ^ [7] Ipsen - David Meek on Ipsen's strategic pillars and hopes in oncology
  13. ^ a b c Fondation Ipsen Archived 1 February 2013 at the Wayback Machine.. Ipsen.com.
  14. ^ a b (in French) Fondation de France. Fondation de France.

External links

  • Ipsen web site
Retrieved from "https://en.wikipedia.org/w/index.php?title=Ipsen&oldid=871815957"
This content was retrieved from Wikipedia : http://en.wikipedia.org/wiki/Ipsen
This page is based on the copyrighted Wikipedia article "Ipsen"; it is used under the Creative Commons Attribution-ShareAlike 3.0 Unported License (CC-BY-SA). You may redistribute it, verbatim or modified, providing that you comply with the terms of the CC-BY-SA